NIPT

The company's cofounders have developed methods for analyzing genetic material from fetal trophoblast cells isolated from the cervix.

The company had a profit of £3.4 million, or £0.01 per share, for the year compared to a loss of £9.6 million, or £0.03 per share, the previous year.

Under the partnership, Heidelberg-based Eluthia will become the primary distributor of BGI's NIFTY noninvasive prenatal test in Germany.

A UK court determined that Ariosa's licensee infringed upon at least one claim of Illumina's European patent 1 524 321 and upheld the patent's validity.

Scientists from the UK and China discussed two new NIPTs that include single-gene disorders and a study to estimate disease recurrence risk in families.

The company's first quarter revenues were driven by sales of its noninvasive prenatal screening and carrier screening tests.

Elucigene has been developing in vitro diagnostics for oncology and reproductive health, including tests for cystic fibrosis screening and prenatal fetal aneuploidy screening.